Lunai Bioworks shares jumped 18% premarket after the company secured its first letter of intent to license its DCCT immune cell therapy. The treatment achieved complete regression of primary and metastatic pancreatic tumors in humanized preclinical models. CEO David Weinstein said the early licensing interest reflects growing confidence in the platforms potential.